Back to top

Editas Medicine, Inc. (EDIT)

(Delayed Data from NSDQ)

$35.00 USD


-0.10 (-0.28%)

Updated Jun 16, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
5Strong Sell3.06%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Cambridge, MA-based Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company’s discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.

Editas has traded publicly since February 2016. It has no marketed drug in its portfolio. The company’s lead pipeline candidate is EDIT-101 that uses CRISPR gene editing to ...

General Information

Editas Medicine, Inc.

11 Hurley Street

Cambridge, MA 02141

Phone: 617-401-9000

Fax: NA



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 8/5/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.85
Current Year EPS Consensus Estimate -3.67
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 8/5/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 35.10
52 Week High 99.95
52 Week Low 27.01
Beta 1.94
20 Day Moving Average 965,798.81
Target Price Consensus 48.86


% Price Change
4 Week 4.56
12 Week -23.83
YTD -49.94
% Price Change Relative to S&P 500
4 Week 1.63
12 Week -29.86
YTD -55.72
Share Information
Shares Outstanding (millions) 67.83
Market Capitalization (millions) 2,380.71
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -24.64%
vs. Previous Quarter 14.00%
Sales Growth
vs. Previous Year 13.56%
vs. Previous Quarter -43.09%
Price Ratios
Price/Book 3.72
Price/Cash Flow NA
Price / Sales 26.02
3/31/21 -28.42
12/31/20 -31.01
9/30/20 -26.74
3/31/21 -20.72
12/31/20 -20.24
9/30/20 -16.38
Current Ratio
3/31/21 9.88
12/31/20 7.20
9/30/20 9.25
Quick Ratio
3/31/21 9.88
12/31/20 7.20
9/30/20 9.25
Operating Margin
3/31/21 -147.51
12/31/20 -127.82
9/30/20 -99.62
Net Margin
3/31/21 -147.51
12/31/20 -127.82
9/30/20 -99.62
Pre-Tax Margin
3/31/21 -147.51
12/31/20 -127.82
9/30/20 -99.62
Book Value
3/31/21 9.44
12/31/20 6.28
9/30/20 7.08
Inventory Turnover
3/31/21 NA
12/31/20 NA
9/30/20 NA
3/31/21 0.00
12/31/20 0.00
9/30/20 0.00
Debt to Capital
3/31/21 0.00
12/31/20 0.00
9/30/20 0.00